-
Cell Death Dis:lncRNA HOXA-AS2 promotes the development of AML by binding EZH2 and inhibiting LATS2
Time of Update: 2020-12-17
previous studies have shown that lncRNA HOXA-AS2 plays an important role as a carcinogen in many tumors, but little is known about its role in AML.
silence HOXA-AS2 inhibits the proliferation of AML cells and induces their differentiation, while over-expression OFSA-AS2 shows the opposite result.
-
Blood: The IDH1 mutation causes myelin dysplate by interfering with hemolybin synthesis and red blood cell production
Time of Update: 2020-12-17
In the red-line cells of these mice, the abnormal metabolite D-2-hydroxypropyt acid (D-2HG) produced by the mutant IDH1 enzyme inhibited the activity of the oxygendic acid dehydrogenase (OGDH), thereby reducing the production of amberyl coenzyme A.
-
ASH 2020: The first human treatment data for the BCMA/CD19 dual-targeted CAR-T treatment of relapsed or difficult-to-treat multiple myeloma are amazing
Time of Update: 2020-12-17
On December 6th Gracell Biotechnology Inc., a global clinical-stage biopharmaceutical company dedicated to the development of efficient and cost-effective cell therapies for cancer, released the results of a phase 1 clinical trial initiated by researchers to assess the safety and effectiveness of its pioneering BCMA/CD19 dual-target CAR-T cell therapy GC012F treatment for relapsed or difficult-to-treat multiple myeloma (R/R MM) patients.
-
China's State Drug Administration has approved a Phase I/II clinical trial of ATG-016 (Eltanexor) to treat high-risk bone marrow growth syndrome
Time of Update: 2020-12-16
recently, China's State Drug Administration (NMPA) has approved a clinical trial of ATG-016 (eltanexor) for the treatment of high-risk bone marrow growth syndrome (MDS).
, the ATG-016 has blood-brain barrier permeability compared to the first generation of SINE, which shows initial anti-cancer activity in patients with high-risk MDS.
-
A selection of Blod research on November 26, 2020
Time of Update: 2020-12-16
1. Kafazomi-Lenadamine-Desamisong joint stem cell transplantation treatment for multiple myeloma https://doi.org/10.1182/blood.2020007522 in multi-center Phase II study (NCT01816971), the researchers evaluated the efficacy of the self-stem cell transplant (ASCT) joint carphetamine-desamisson (KRd) program in newly diagnosed patients with multiple myeloma (NDMM).
-
JAHA: Direct oral anticoagulants and venous thromboembolism in patients with hereditary haemophilia
Time of Update: 2020-12-16
VTE and hereditary haemophilia patients treated with DOAC (case) or heparin/vitamin K antagonists (control group) were matched by age, sex, race, and type of thrombosis.
-
Brit J Cancer: The prognostic value of NLR in patients with advanced pulmonary large cell neuroendocrine cancer and its relationship to the micro-environment of immuno-related tumors
Time of Update: 2020-12-16
, researchers conducted a retrospective study to assess the relationship between pre-treatment NLR and clinical outcomes in patients with advanced LCNEC, as well as the effects of immuno-related tumor microeconients (TME), in a recent study published in British Journal of Cancer, an authoritative journal in the field of oncology.
-
Breakthrough in relapsed AML therapy: Golden Biotech reports on the progress of Antroquinonol's trial
Time of Update: 2020-12-16
Golden Biotechnology, Taiwan's leading biopharmaceutical company, recently announced that its new drug, Antroquinonol (Hocena), is superior to other drugs listed in Phase II clinical trials for treatable relapsed AML (acute myeloid leukemia).
-
NEJM: Devasalban studied the prevention effects of cardiovascular events in people with atrial fibrillation and two-tip flap implants
Time of Update: 2020-12-16
in patients with atrial fibrillation and two-tip valve biolobe implants, devasalban therapy was superior to warfarin in reducing the risk of death, major cardiovascular events or haemorrhage within 12 months.
-
Blood:miR-29 regulates the CD40 signal in the CLL micro environment via TRAF4
Time of Update: 2020-12-16
summary model diagram, the study demonstrates for the first time the miRNA-dependent mechanism for activating CD40 signal/T cell interactions in the CLL micro-environment, and describes a new miR-29-TRAF4-CD40 signal axis regulated by BCR activity.
-
Blood: Changes in the risk of venous thromboembolism in cancer patients from 1997 to 2017
Time of Update: 2020-12-16
the risk of VTE over time was unexpected, the incidence of venous thromboembolism in cancer patients did not decrease with advances in treatment, but increased significantly: the cumulative incidence of 12 months in the cancer queue increased from 1.0% (95% CI 0.9% in 1997) -1.2%) rose to 3.4% (95% CI 2.9%-4.0%) in 2017, but the use of ct scans, chemotherapy and targeted therapy increased significantly and the 12-month survival rate increased significantly.
-
Blood: Blood red inhibits the body fluid B cell response in SCD patients to regulate the same immune risk
Time of Update: 2020-12-16
all, these data suggest that hemolytic blood can inhibit the response of B-cells, which may be a factor in the same immune risk in patients with SCD.
-
JAMA: Childhood lead exposure is associated with decreased brain structural integrity and cognitive ability in middle age
Time of Update: 2020-12-16
A new study published recently in JAMA validates the hypothesis that lead exposure in children is associated with lower structural integrity of the brain in middle age, and this longitudinal prospective cohort study of 564 middle-aged New Zealand-children showed a significant correlation between excessive lead exposure in childhood and MRI measurements of brain structure at age 45, including smaller cortical surface area, smaller hippocupus, lower overall heterogeneity scores, and lower brain aging.
-
Blood: Long-term neurodevelopmental results of hematopoietic stem cell transplantation to treat krabbe disease in late-haired infants
Time of Update: 2020-12-16
, the study showed that hematopoietic stem cell transplants extended the lifespan of patients with advanced Krabbe disease and improved their basic cognitive and speech skills, especially those who received transplants before symptoms appeared.
-
Nat Aging: What are the healthy aging characteristics of human monocytes?
Time of Update: 2020-12-16
here, the researchers report on the full features of healthy aging of classical human monocytes, focusing on changes in the exogenomic genome, transcriptions, and proteomics, as well as corresponding proteomic and plasma metabolic data.
-
"Please answer 1988" Yu Yu played by leukemia recurrence, leukemia after the cure why relapse?
Time of Update: 2020-12-16
First of all, we need to know that leukemia is a malignant cloning disease of bone marrow hematopoietic stem cells, although at present, with the improvement of leukemia treatment technology, the full remission rate and survival of acute leukemia has been significantly improved, but there will still be most patients in clinically induced remission after the disease will relapse.
-
NICE guidelines support isatuximab treatment for multiple myeloma (MM)
Time of Update: 2020-12-16
some of the data we have seen from our committee suggest that Sarclisa combined pomalidomide and dexamisson can slow the progression of the disease and extend the life of patients compared to current treatment options." multiple myeloma is a malignant tumor (cancer) that causes abnormal growth of plasma cells that invade the bone marrow.
-
NICE supports Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukemia
Time of Update: 2020-12-11
The National Institutes of Health and Clinical Optimization (NICE) has published guidelines in support of AstraZenecom's Calquence as a treatment for chronic lymphocytic leukemia (CLL).
-
Is Li Ka-shing's superstitious "life-long medicine" a medical miracle or a cut?
Time of Update: 2020-11-30
li Ka-shing, his health care products cost 1.5 million yuan a year to take, and if clinical trials are to be conducted, who will pay for them?
-
Abel Vinaykla film is about to be approved domestic sales are expected to break 1 billion this year...
Time of Update: 2020-11-30
Recently, AbbVie BCL-2 inhibitor "Venecla tablet" market application (JXHS2000002/3/4) entered the administrative approval stage, which means that the drug will soon be approved in China, approved adaptation Symptoms are: combined aza cytosine, or tesythytoside, or low-dose agarose cytosine is used to treat patients with acute myeloid leukemia (AML) in adults aged 75 years and older or who are not suitable for a new diagnosis of strong induced chemotherapy due to co-merger.
